Late Onset Prosthetic Hip Joint Infection in Two Patients of Rheumatoid Arthritis Treated With Etanercept

Late onset infection developing after THA following etanercept therapy in RA indicates that tumor necrosis factor-alpha blockers should be carefully administered in patients who have undergone THA.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:In this article, we report two rheumatoid arthritis (RA) patients who developed rare, late onset infection after total hip arthroplasty (THA) following etanercept therapy.

📊

Key Findings & Data:First patient was a 74-year-old female with RA.

💡

Conclusion & Impact:Late onset infection developing after THA following etanercept therapy in RA indicates that tumor necrosis factor-alpha blockers should be carefully administered in patients who have undergone THA.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

In this article, we report two rheumatoid arthritis (RA) patients who developed rare, late onset infection after total hip arthroplasty (THA) following etanercept therapy. First patient was a 74-year-old female with RA. Treatment with etanercept was initiated three years after THA, and infection involving THA was observed two months after the initiation of etanercept. Patient was successfully treated by open debridement. Second patient was a 62-year-old female with RA. THA was performed, and infection involving THA was observed four years after the initiation of etanercept. This patient was also successfully treated by open debridement. However, when etanercept was reinitiated two years after open debridement, infection reoccurred. Immediately, open debridement was performed, prosthesis was removed, and antibiotic-impregnated, cement spacer was inserted. THA was repeated two months after open debridement. Late onset infection developing after THA following etanercept therapy in RA indicates that tumor necrosis factor-alpha blockers should be carefully administered in patients who have undergone THA.

🔖

Cite This Article

SHINYA, H., YOSHITADA, S., TAKAAKI, F., SHINGO, H., NORIYUKI, K., RYOSUKE, K., MASAHIRO, K. (2015). Late Onset Prosthetic Hip Joint Infection in Two Patients of Rheumatoid Arthritis Treated With Etanercept. art, Cilt: 30 - Sayı: 2, 168–171. https://ajindex.com/articles/351704

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (8)

Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63
Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006;55:333-7
Ruyssen-Witrand A, Gossec L, Salliot C, Luc M, Duclos M, Guignard S, et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol 2007;25:430-6
Yurube T, Takahi K, Owaki H, Fuji T, Kurosaka M, Doita M. Late infection of total knee arthroplasty inflamed by anti-TNFalpha, Infliximab therapy in rheumatoid arthritis. Rheumatol Int 2010;30:405-8
Salliot C, Gossec L, Ruyssen-Witrand A, Luc M, Duclos M, Guignard S, et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 2007;46:327-34
Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:1810-4
Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007;56:1754-64. 8. den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 2007;34:689-95
Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005;44:157-63.